novo nordisk semaglutide clinical trials announced headline results from STEP UP, a phase IIIb trial investigating subcutaneous 7.2 mg for obesity Latest Competitive Analysis of Novo

Piling more appetite suppression on top can work against the exact edge that makes retatrutide different in the first place

On December 12th 2025, Novo launched Ozempic in India, pricing the lowest 0.25-mg dose at $24.35 per week, to capture market share while its patent is still valid

Interestingly, despite its primary diabetes management indication, Mounjaros utility in weight management has been recognized, particularly after its MHRA endorsement in the UK for adult weight loss and management, thus broadening its applicability beyond diabetes

According to the MHRA SmPC, semaglutide does not reduce the efficacy of hormonal contraceptives, though severe vomiting or diarrhoea may potentially affect the absorption of oral contraceptive pills, requiring temporary additional contraceptive measures